-+ 0.00%
-+ 0.00%
-+ 0.00%

Xenon submits FDA NDA for azetukalner in focal seizures

PUBT·09/17/2026 20:01:44
Listen to the news
Xenon submits FDA NDA for azetukalner in focal seizures
  • Xenon submitted an FDA New Drug Application for azetukalner to treat focal seizures.
  • Filing supported by positive Phase 2b X-TOLE and Phase 3 X-TOLE2 data showing statistically significant cuts in monthly seizure frequency.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609171601PRIMZONEFULLFEED9829210) on September 17, 2026, and is solely responsible for the information contained therein.